首页> 美国卫生研究院文献>Non-coding RNA Research >Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?
【2h】

Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?

机译:非编码RNA时代的主动脉瓣钙化:主动脉瓣狭窄管理方面的革命?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aortic valve stenosis remains the most frequent structural heart disease, especially in the elderly. During the last decade, we noticed an important consideration and a huge number of publications related to the medical and surgical treatment of this disease. However, the molecular aspect of this degenerative issue has also been more widely studied recently. As evidenced in oncologic but also cardiac research fields, the emergence of microRNAs in the molecular screening and follow-up makes them potential biomarkers in the future, for the diagnosis, follow-up and treatment of aortic stenosis. Herein, we present a review on the implication of microRNAs in the aortic valve disease management. After listing and describing the main miRNAs of interest in the field, we provide an outline to develop miRNAs as innovative biomarkers and innovative therapeutic strategies, and describe a groundbreaking pre-clinical study using inhibitors of miR-34a in a pre-clinical model of aortic valve stenosis.
机译:主动脉瓣狭窄仍然是最常见的结构性心脏病,尤其是在老年人中。在过去的十年中,我们注意到了与该疾病的医学和外科治疗有关的重要考虑因素和大量出版物。但是,该变性问题的分子方面最近也得到了更广泛的研究。正如在肿瘤学和心脏研究领域所证实的那样,microRNA在分子筛查和随访中的出现使它们成为将来用于诊断,随访和治疗主动脉狭窄的潜在生物标志物。在这里,我们提出了对microRNA在主动脉瓣疾病管理中的意义的审查。在列出并描述了该领域感兴趣的主要miRNA之后,我们概述了开发miRNA作为创新生物标志物和创新治疗策略的概况,并描述了在主动脉临床前模型中使用miR-34a抑制剂进行的突破性临床前研究。瓣膜狭窄。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号